Bigfoot Biomedical said today that it inked a non-exclusive deal with Eli Lilly (NYSE:LLY) to integrate Eli Lilly’s insulin products into Bigfoot’s investigational insulin delivery devices.
The California-based company expects to launch its first two insulin delivery systems – Bigfoot Inject and Bigfoot Loop – in 2020, contingent upon finishing a pivotal trial and landing regulatory approvals.
Get the full story at our sister site, Drug Delivery Business News.
The post Bigfoot Biomedical inks insulin deal with Eli Lilly appeared first on MassDevice.
from MassDevice http://bit.ly/2Vy5HqR
Cap comentari:
Publica un comentari a l'entrada